Business Wire

Pharnext Reports Year End 2016 Financial Results


Regulatory News:

Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today reported its financial and operational results for the year ended December 31, 2016.


Over the course of year, in line with the objectives announced at the time of its IPO, Pharnext rolled out the international Phase 3 trial of its lead clinical candidate PXT3003 for the treatment of Charcot-Marie-Tooth type 1A (CMT1A) disease: patient enrollment was completed in December 2016 as planned (323 patients in total across 3 arms). This pivotal 15-month Phase 3 trial is being conducted at 29 sites including 17 in Europe, 11 in the United States (U.S.) and one in Canada. The first pre-specified evaluation of PXT3003 safety data was conducted in November 2016 by the independent Data Safety Monitoring Board (DSMB). Based on this review, the DSMB recommended continuing the study as planned.

Regarding PXT864, its second lead drug in clinical development for the treatment of Alzheimer’s disease, Pharnext completed the results analysis of its Phase 2a study. The Company was invited to present these promising results during the annual CTAD (Clinical Trials on Alzheimer’s Disease) congress organized in San Diego in December 2016.

Pharnext’s listing on the Euronext Alternext stock exchange in July 2016, a key milestone for the year, enabled the Company to strengthen its equity and its cash by raising 30,9m€. The convertibles bonds held by historic shareholders were converted into equity.


The main elements of the year-end 2016 financials are set out in the table below: these are taken from the financial statements drawn up under IFRS, which were approved by the Board of Directors at its meeting on April 20, 2017. The audit procedures have been carried out and the auditors’ report relating to the certification of the accounts is in the process of being issued. The full financial statements are available on the Company’s website:

Selected financial information (IFRS financial statements)
In kilo euros   2016   2015
Operating Revenues   4 436   2 631
Research and Development expenses (13 647) (7 649)
SG&A expenses (4 177) (3 613)

Operating Income

(13 389) (8 631)

Net Financial Income

(4 058) (2 364)

Earnings before tax

(17 447) (10 994)
Basic earnings per share (in €)   (2,1)   (1,7)

Net cash flows used in operating activities

(12 553) (9 173)

Net cash flows used in financing activities

26 902 5 257

Net cash movement

13 581 (4 148)

Cash and cash equivalents at the end of the period

  16 670   3 089

Operating revenues for the full year of 2016 was mainly generated by the Company’s research tax credit (3,8m€ for the 2016 period) and subsidies.
The increase in Research and development expenses is directly linked to the deployment of the PXT3003 Phase 3 clinical trial.The Financial income is affected, in 2016, by considering, at the level of financial costs, conversion premiums of convertible bond, subscribed in 2014.
Net cash flows used in operating activities were 12,6m€ in 2016: the increase compared to previous period resulted essentially from Phase 3 deployment.
Net cash flows used in financing activities consist mainly, in 2015, of a 5m€ venture loan, and in 2016, of a 2nd tranche of loan of 2.5m€, then of the net proceeds from the issuance of shares during the IPO (28.2m€). In 2016, loan reimbursements and payment of interest charges accounted for 3,5m€.


Over the current financial year, Pharnext is continuing its Phase 3 clinical trial for its drug candidate PXT3003 in CMT1A. The last patient dosed is expected to complete this 15-month pivotal study in March 2018. In between, a futility analysis will be initiated in October 2017. Results of the futility analysis will be published as soon as they will become available.

Beyond the 15-month pivotal study, for which top-line results will be reported during the second quarter of 2018, patients will continue their treatment in a 9-month follow-up extension study designed to assess the long-term safety of PXT3003. This follow-up extension study, which began in March 2017, will continue throughout the year.

In parallel to the above mentioned clinical studies, the Company also initiated new preclinical studies to complement the existing synergy data on PXT3003. At the end of the 15-month pivotal study, if positive, Pharnext plans to submit an application dossier for PXT3003 marketing authorization to the European regulatory authorities (EMA: European Medicine Agency) and U.S. authorities (FDA: Food and Drug Administration).

In addition, after obtaining promising preliminary results in the Phase 2a trial for PXT864 in Alzheimer's disease, the Company will continue the design of the protocol of a Phase 2b study, which is expected to launch by the end of 2017.

Finally, following the signature of a research and development partnership early in March with Galapagos NV, on the creation of a new pipeline of novel synergistic drug combinations, Pharnext plans new agreements with other parties.

Thus, Pharnext is currently in advanced discussion on several international industrial strategic agreements. These agreements would contain business licenses, development of new pipelines and minority investments in equity with a premium on the current stock market price.

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics: Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit

This press release contains certain forward-looking statements concerning Pharnext and its business. Such forward-looking statements are based on assumptions that Pharnext considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the Document de référence registration document filed with the Autorité des marchés financiers (AMF- French Financial Market Authority) on July 28, 2016 under n°R.16-069 and to the development of economic conditions, financial markets and the markets in which Pharnext operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Pharnext or not currently considered material by Pharnext. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Pharnext to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Pharnext shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

Contact information

Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Media Relations (Europe)
Caroline Carmagnol
Margaux Pronost
+33 (0)1 44 54 36 64
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1 212-362-1200
Media Relations (U.S.)
Russo Partners
Tony Russo, Ph.D.
Scott Santiamo
+1 212-845-4251
+1 212-845-4235
Investor Relations (France)
Julie Coulot, +33 (0)1 44 71 20 40

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Summer Business with New Shop Feature and High-Performance Tyre Models16.3.2018 14:11Pressemelding

Each year, summer trade means great challenges for car garages and tyre dealers. As a result and at just the right time,, the online trade customer shop by Europe’s leading online tyre dealer Delticom, is introducing a new feature intended to make the daily work of the shop’s customers easier: An advice mode is available from now on at When changing from the purchasing to the sales view, the individual end customer prices are displayed instead of the actual purchase prices. In order to use this feature, users of simply have to insert their individual markups for the different item groups. From the markup and the purchase price, the online shop automatically calculates the personal end customer price. The usual purchasing view is also still available. This press release features multimedia. View the full release here: An advice mode immediately helps trade customers use the full pot

Available Now: The Smartphone Made for the Way We Communicate Today, the Galaxy S9 and S9+16.3.2018 12:00Pressemelding

Samsung Electronics America, Inc. announced that the new, award-winning Galaxy S9 and Galaxy S9+, which have been recognized by smartphone reviewers worldwide for their best-in-class display, design and camera, are now available for purchase at U.S. wireless network providers and retail stores. The phones come in three colors: Midnight Black, Coral Blue, and the new Lilac Purple. The Galaxy S9 has a suggested retail price of $719.99, while the Galaxy S9+ is available for $839.99. Both unlocked and carrier versions of the Galaxy S9 and Galaxy S9+ are also available for purchase on This press release features multimedia. View the full release here: Designed for the way we communicate today, Samsung's new Galaxy S9 and Galaxy S9+ are available in the U.S. at wireless network providers, retailers and on (Photo: Business Wire) “The Galaxy S9 and S9+ are designed for the visual and social generation—the consum

CONQUEST Group Announced the Expansion of its Asset Management Business with the Appointment of Philippe Taillardat to the Role of Director16.3.2018 09:00Pressemelding

Philippe Taillardat brings to CONQUEST over 25 years of Asset Management and Investment Banking experience, primarily in principal investing, financial advisory, equity and debt financing across global infrastructure and sustainable energy sectors. This press release features multimedia. View the full release here: Philippe Taillardat (Photo: CONQUEST Group) Philippe was most recently Co-Head of Infrastructure Investments Europe at First State Investments, which he helped transform into one of the leading billion+ European infrastructure fund manager in core / core+ strategies. Earlier in his career, Philippe held various senior banker and investment roles at Amundi, Credit Agricole CIB, Credit Suisse, AXA and BNP Paribas. Frédéric Palanque, Managing Director of CONQUEST Group, said, "We are delighted to welcome such a recognized professional. CONQUEST is trusted for providing value-added advice in complex and highly confidential

AccelStor All-Flash Solutions Unlock Data Possibilities for AI and Cloud16.3.2018 09:00Pressemelding

AccelStor, an innovative all-flash array (AFA) provider for the big data era, is excited to announce its participation in the upcoming Cloud Expo Europe, taking place from March 21 to 22 at Booth C1850 in the ExCel London exhibition centre. Besides presenting latest all-flash storage solutions breaking through performance and availability barriers for artificial intelligence (AI), virtualization and private cloud, AccelStor will present a live demonstration of its new generation NeoSapphire high availability models, one of the highlights not to be missed this year. This press release features multimedia. View the full release here: AccelStor's new generation NeoSapphire High Availability all-flash array AccelStor NeoSapphire all-flash arrays are highly integrated with virtualization and private cloud platforms, supporting VMware vSphere and OpenStack Cinder. NeoSapphire’s “high availability” series features symmetric active-activ

Westinghouse Completes First Major Decommissioning Work at a Nordic Commercial Nuclear Reactor16.3.2018 08:45Pressemelding

Westinghouse Electric Company announced today that it has completed a major decommissioning project at the former Barsebäck nuclear power plant in Skåne, Sweden. Barsebäck Unit 2 ceased operation in 2005 and decommissioning work began in August 2016. Westinghouse’s scope of work included the underwater segmentation and packaging of the reactor vessel internals, as well as the upfront engineering studies and equipment manufacturing and qualification. “Westinghouse is proud to deliver this major decommissioning project on time and on budget,” said Yves Brachet, Westinghouse senior vice president, Global Decommissioning, Decontamination, Remediation and Waste Management. “Our global expertise in this area will help our customers in the Nordic region to safely manage a variety of end-of-life opportunities for commercial nuclear power plants.” Leadership at Barsebäck Kraft AB (BKAB) is equally satisfied with this successful initial step of the first dismantling of a commercial nuclear power

Lighting Manufacturer LTS Licht & Leuchten, Part of the Fargerhult Group, to Offer Selected Spot- & Downlights with Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs16.3.2018 08:02Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs, which implement light closest to the spectrum of natural sunlight, has been adopted for selected luminaires of LTS Licht & Leuchten GmbH, a German manufacturer of high-quality luminaires for hospitality, retail, and office applications. This press release features multimedia. View the full release here: LTS Jett 100 spotlights equipped with SunLike LED technology (Photo: Business Wire) LTS has adopted SunLike natural spectrum LEDs for selected products, including the Jett 100 and CSA 60 spotlights. A series of spotlights with a discreet and individual appearance, and clear, straightforward design lines, Jett spotlights harmoniously blend in with any type of retail application. The high color rendering and superior luminous intensity of these spotlights enable lighting designers to achieve accentuated ar